Concepedia

Author

Opeyemi Soremekun

University of KwaZulu-NatalORCID

Also Known As

Opeyemi S Soremekun, Opeyemi S. Soremekun, Opeyemi Soremekun, Soremekun, Opeyemi

102

Publications

872

Citations

17

H-Index

61

Concepts

All Affiliations

University of KwaZulu-NatalLondon School of Hygiene & Tropical MedicineUganda Virus Research InstituteImperial College LondonUniversity of the Witwatersrand
OS

About

Opeyemi Soremekun is an author at University of KwaZulu-Natal specializing in medicine, drug discovery, and medicinal chemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

110

2

Natural Sciences

2

2

34

3

Public Health

2

2

50

4

Engineering

1

1

15

5

Health Sciences

1

1

32

Opeyemi Soremekun

×

22

Publications

549

Citations

15

H-Index

YearCitations

Transferability of genetic risk scores in African populations

Abram Bunya Kamiza, Sounkou M. Touré, Marijana Vujković,

Nature Medicine

2022

112

The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian-randomization study

Christopher Kintu, Opeyemi Soremekun, Abram Bunya Kamiza,

EBioMedicine

2023

55

Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study

Opeyemi Soremekun, Ville Karhunen, Yiyan He,

EBioMedicine

2022

41

Metabolic Traits and Stroke Risk in Individuals of African Ancestry: Mendelian Randomization Analysis

Segun Fatumo, Ville Karhunen, Tinashe Chikowore,

Stroke

2021

33

Production, Nutritional and Microbiological Evaluation of Mahewu a South African Traditional Fermented Porridge

I. F. Fadahunsi, Opeyemi Soremekun

Journal of Advances in Biology & Biotechnology

2017

32

Thompson loop: opportunities for antitubercular drug design by targeting the weak spot in demethylmenaquinone methyltransferase protein

Adeniyi T. Adewumi, Opeyemi Soremekun, Mary B. Ajadi,

RSC Advances

2020

27

Weak spots inhibition in the <i>Mycobacterium tuberculosis</i> antigen 85C target for antitubercular drug design through selective irreversible covalent inhibitor-SER124

Adeniyi T. Adewumi, Ahmed A. El‐Rashedy, Opeyemi Soremekun,

Journal of Biomolecular Structure and Dynamics

2020

22

Recruiting monomer for dimer formation: resolving the antagonistic mechanisms of novel immune check point inhibitors against Programmed Death Ligand-1 in cancer immunotherapy

Opeyemi Soremekun, Fisayo A. Olotu, Clement Agoni,

Molecular Simulation

2019

21

Exploring the ring potential of 2,4-diaminopyrimidine derivatives towards the identification of novel caspase-1 inhibitors in Alzheimer’s disease therapy

Ransford Oduro Kumi, Opeyemi Soremekun, Abdul Rashid Issahaku,

Journal of Molecular Modeling

2020

21

Development of Halogenated Pyrazolines as Selective Monoamine Oxidase-B Inhibitors: Deciphering via Molecular Dynamics Approach

Aathira Sujathan Nair, Jong‐Min Oh, Vishal Payyalot Koyiparambath,

Molecules

2021

19

Page 1